, Tracking Stock Market Picks
Enter Symbol:
Curis, Inc. (CRIS) [hlAlert]

up 10.13 %

Curis, Inc. (CRIS) rated Buy with price target $6 by Brean Murray

Posted on: Tuesday,  Jan 31, 2012  8:25 AM ET by Brean Murray

Brean Murray rated Buy Curis, Inc. (NASDAQ: CRIS) on 01/31/2012. Previously Brean Murray rated Buy Curis, Inc. (NASDAQ: CRIS) on 10/08/2009.,
when the stock price was $2.27. Since then, Curis, Inc. has gained 10.13% as of 01/22/2016's recent price of $2.50.
If you would have followed the previous Brean Murray's recommendation on CRIS, you would have gained 10.13% of your investment in 2297 days.

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease.

Our equity research department is focused on fundamental analysis across the universe of over 200 small/mid cap stocks in our five target sectors. We are committed to providing proprietary action-oriented research to our institutional clients. Small cap growth focus. Our primary area of concentration is growth stocks with market capitalization of $200 million to $5 billion. Global perspective. We are covering U.S. listed stocks for companies domiciled in the U.S., China, Europe and Latin America, with our biggest concentration in the US and China. We were one of the first banks to aggressively expand our research to China and we believe we created one of the premier research franchises in small cap, U.S. listed Chinese companies to complement our strong domestic coverage. Disciplined stock selection. Our research analysts are focused on performing extensive bottoms up due diligence on companies under our coverage by leveraging their industry and management contacts. By combining our bottoms up work with our sector views we seek to generate a consistent flow of high conviction ideas for our clients. Diversified coverage. Our areas of expertise include technology, consumer, healthcare, resources and China small cap. We provide our clients with company-specific as well as sector-specific research across our target sectors.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/31/2012 8:25 AM Buy
4.93 6.00
as of 12/31/2012
1 Week down  -6.28 %
1 Month up  2.38 %
3 Months down  -17.14 %
1 YTD down  -26.70 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/29/2011 8:25 AM Buy
4.16 5.00
3/21/2011 1:25 PM Buy
3.29 5.00
10/8/2009 8:25 AM Buy
2.27 4.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy